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ABSTRACT
Introduction: Breakthrough pain is common
among patients with cancer and presents
challenges to effective pain management.
Breakthrough pain is characterized by rapid
onset, severe intensity, and duration typically
lasting \1 h. Thus, optimal relief from
breakthrough pain is best attained by
administering analgesics with dissolution times
and bioavailabilities that closely match the onset
and duration of breakthrough pain. The objective
of this study was to assess complete disintegration
time of three different doses of sublingual
fentanyl tablets in opioid-tolerant patients.
Methods: This was a single-center, non-
randomized, open-label study. Opioid-tolerant
adult patients (N = 30) with chronic pain were
assigned to one of three dose groups and self-
administered a single 100, 200, or 300 lg
sublingual fentanyl tablet (Abstral, Galena
Biopharma, Portland, OR, USA). Time to
complete disintegration was measured by each
patient with a stopwatch and independently
verified by study personnel.
Results: Disintegration time (mean ± SD) for
sublingual fentanyl tablets (all doses) was
88.2 ± 55.1 s. Mean disintegration times
tended to be slightly longer for the 200 lg
(96.7 ± 57.9 s) and 300 lg doses (98.6 ± 64.8 s)
compared to the 100 lg dose (69.5 ± 40.5 s).
Differences were not statistically significant.
Disintegration time was not significantly
different between men and women and was
not affected by age.
Conclusion: Sublingual fentanyl tablets
dissolved rapidly (average time \2 min) in all
patients, with the higher doses taking slightly
more time to dissolve.
Keywords: Breakthrough pain; Dissolution
time; Dwell time; Sublingual fentanyl tablets;
Transmucosal immediate release fentanyl
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INTRODUCTION
Breakthrough pain is prevalent (41–95%)
among patients with cancer [1, 2] and presents
challenges to effective pain management [2, 3].
Breakthrough pain typically exhibits a rapid
onset (typically \5 min, ranging from 1 s to
30 min until peak intensity), severe intensity,
and lasts for\1 h, but may last for up to 1 to 2 h
[4, 5]. Therefore, optimal relief from
breakthrough pain is best attained by
administering analgesics which have
pharmacokinetics and pharmacodynamics that
closely match the time course of breakthrough
pain events.
The transmucosal route of administration of
analgesics can avoid first-pass hepatic
metabolism and allow rapid entry of drugs into
the systemic circulation [6, 7]. It can also yield
increased bioavailability relative to orally
administered drugs [8]. Current clinical
guidelines recommend transmucosal fentanyl
as an option for the relief of breakthrough
cancer pain [9]. A variety of transmucosal
fentanyl products with different routes of
administration (e.g., lozenge, buccal tablet,
buccal film, sublingual tablet, sublingual spray,
and nasal spray) are available. A novel
sublingual tablet form of fentanyl (Abstral;
Galena Biopharma, Portland, OR, USA) was
developed that would undergo rapid
disintegration and absorption within the time
of onset and duration of breakthrough pain [10].
The subjective nature of pain is reflected in
the highly variable and individualized
responses to pain therapies. Patient perception
of ‘‘dwell time’’ contributes to preference, which
in turn can affect compliance rates [11].
Previous studies have demonstrated the
efficacy of sublingual fentanyl tablets in the
treatment of breakthrough pain in patients who
are opioid tolerant [12, 13]. Preliminary
assessments of the disintegration time and
patient acceptability of this fentanyl
formulation have been previously presented
[14–16]. Here, we present a detailed assessment
of patient perception of the complete
disintegration time of sublingual fentanyl
tablets in practice-based, opioid-tolerant
patients. Measurement of pain relief was not
an objective of this study.
METHODS
Study Population
Men and women aged 18–75 years with chronic
pain who were tolerant to opioids (i.e.,
morphine 60 mg/day or equivalent
for C1 week) were eligible for enrollment in
the study. Women of child-bearing potential
had to be using an acceptable form of birth
control to participate in the study. Exclusion
criteria included: allergy to fentanyl or its
derivatives; history of severe chronic
obstructive pulmonary disease; or asthma that,
in the investigator’s opinion, was medically
significant. Pregnant or lactating women and
patients deemed by the investigator to be
medically unstable were also excluded from
the study.
Study Design
This single-center, non-randomized, open-label
study was designed to enroll a minimum of 10
patients in each of 3 dose groups. The primary
objective was to assess patient-reported time for
complete disintegration of 3 different doses of
sublingual fentanyl oral disintegrating tablets in
opioid-tolerant patients. The design of the
study was approved by an independent
institutional review board (Ethical and
Independent Review Committee, Inc.,
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Independence, MO, USA) and the study was
conducted in accordance with US Food and
Drug Administration regulations for the
conduct and monitoring of clinical
investigations. Procedures were in accordance
with Good Clinical Practice and International
Conference on Harmonisation guidelines, and
with the Declaration of Helsinki of 1975, as
revised in 2000 and 2008. All patients provided
written informed consent before initiation of
study procedures.
During the training phase, patients were
given a placebo matching the sublingual
fentanyl tablet to ensure optimal sublingual
placement of the tablet and to establish
familiarity with the product dissolution and
assessment of disintegration time. During the
subsequent evaluation phase, each patient self-
administered a single 100, 200, or 300 lg
sublingual fentanyl tablet. Patients received
the appropriate dose of study drug (as
determined by the investigator) in an
outpatient setting; all patients who were naive
to rapid-acting fentanyl received sublingual
fentanyl 100 lg. Patients being treated with
other rapid-acting fentanyl products [e.g.,
Actiq (fentanyl citrate oral transmucosal
lozenge; Cephalon, Inc., Frazer, PA, USA),
Fentora (fentanyl citrate buccal tablet;
Cephalon, Inc., Frazer, PA, USA), or Onsolis
(fentanyl buccal soluble film; Meda
Pharmaceuticals, Inc., Somerset, NJ, USA)]
were given the equivalent of 50% of their dose
at that time, to the nearest lower strength of
sublingual fentanyl (not to exceed 300 lg).
Patients were permitted to use all concurrent
medications, including long-acting opioids, for
the duration of this study. However, patients
were instructed not to use other forms of rapid-
acting fentanyl, including Actiq, Fentora,
Onsolis, or Abstral, for breakthrough pain for
2 h before and after the administration of study
drug [17–20]. Adherence to this requirement
was independently confirmed by study
personnel.
Assessments
Time to complete disintegration was defined as
the time post-administration when the patient
felt that the sublingual tablet had completely
dissolved under the tongue, as measured by
each patient with a stopwatch and
independently verified by study personnel.
Any adverse events (AEs) believed to be
expected or unexpected, whether reported by
the patient or noted by the investigator, were to
be recorded.
Statistical Methods
Descriptive statistics were used to summarize
pooled data from the individual treatment
groups. Analyses were performed using Prism
v5.04 (GraphPad Software, Inc., La Jolla, CA,
USA). One-way analysis of variance (ANOVA),
followed by the Bonferroni post hoc test, was
used to compare the total disintegration times
among the groups administered the 3 strengths
of sublingual fentanyl. A 2-tailed unpaired t test
was used to assess the difference in
disintegration time between men and women
across all doses of sublingual fentanyl. Linear
regression analysis was used to assess the effects




Pooled baseline demographics of patients in all
treatment groups are summarized in Table 1.
The mean age for all patients in this study was
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54 years (range 36–74 years) with more women
(18/30; 60%) than men. Maintenance and
breakthrough pain treatments for the study
population are listed in Table 2.
Disintegration Time of Sublingual
Fentanyl
The disintegration time (mean ± SD) for the
sublingual placebo used during training was
107.1 ± 73.4 s. The disintegration time for
sublingual fentanyl across all doses was
88.2 ± 55.1 s; there was a non-significant trend
toward longer disintegration times for the 200
lg (96.7 ± 57.9 s) and 300 lg (98.6 ± 64.8 s)
sublingual fentanyl doses compared with the
100 lg sublingual fentanyl dose (69.5 ± 40.5 s;
Fig. 1). Disintegration time for sublingual
fentanyl across all doses was similar between
men and women (Fig. 2), and was not affected
by age (Fig. 3). No AEs occurred during the
study.
DISCUSSION
The persistently high prevalence of
breakthrough pain in patients with cancer
indicates an ongoing need for rapidly acting
analgesics with pharmacokinetic properties that
match the rapid onset and short duration of
breakthrough pain [21, 22]. Although several
rapid-acting fentanyl analgesics [Abstral, Actiq,
Fentora, Onsolis, Subsys (fentanyl sublingual
spray; INSYS Therapeutics, Inc., Chandler, AZ,
USA), and Lazanda (fentanyl nasal spray;
Depomed, Newark, CA, USA)] are currently






Mean age, years (range)
All patients 54 (36–74)
Men 52 (36–74)
Women 56 (38–74)
Table 2 Analgesic treatment history
Patients
(N5 30)
Maintenance treatment, n (%)
Fentanyl transdermal system 8 (27)
Methadone 3 (10)
Oxycodone controlled release 3 (10)
Fentanyl 2 (7)
Hydrocodone and acetaminophen 2 (7)
Hydromorphone extended release 2 (7)




Oxymorphone extended release 2 (7)




Breakthrough pain treatment, n (%)
Fentanyl buccal tablet 12 (40)
Fentanyl oral transmucosal lozenge 6 (20)
Fentanyl sublingual tablet 2 (7)
Hydrocodone and acetaminophen 2 (7)
Oxycodone 2 (7)
Oxymorphone immediate release 2 (7)
Buprenorphine 1 (3)
Morphine sulfate extended release 1 (3)
Oxycodone and acetaminophen 1 (3)
Tramadol extended release 1 (3)
124 Pain Ther (2013) 2:121–128
123
available, these products are not therapeutically
interchangeable, and there may be considerable
differences in patient preferences [17–20, 23,
24]. Sublingual fentanyl, with a novel
mucoadhesive, is an effective analgesic for the
management of breakthrough cancer pain [12,
13]. In the present study, sublingual fentanyl
exhibited rapid disintegration times and high
levels of bioavailability consistent with the ease
of administration of this form of fentanyl.
Perceptions of disintegration time (or ‘‘dwell
time’’) could be a factor in patient preference,
although direct evidence is currently lacking.
Several earlier generation fentanyl products
currently used for the relief of breakthrough
pain employ different methods of drug delivery
(e.g., lozenge, buccal tablet, film) and should be
held in the mouth for approximately 15–30 min
to achieve drug dissolution [17–19]. These
relatively long dwell times may not be optimal
for the relief of breakthrough pain. The present
study assessed the patient’s perception of
complete disintegration time and taste of 3
doses (100, 200, or 300 lg) of rapid-acting
sublingual fentanyl. The results showed that
sublingual fentanyl rapidly disintegrated, with
the time to patient-reported complete
disintegration ranging from 69.5 s in the 100
lg dose group to 98.6 s in the 300 lg dose
group. Although there were no significant
differences in disintegration time between
sublingual fentanyl dose groups, this study
was not powered for statistical analysis. The
mean disintegration time across all doses of
sublingual fentanyl did not differ significantly
by age or sex. Patients in this study were
exposed to placebo tablet training prior to
sublingual fentanyl administration. Using a
sublingual placebo tablet to familiarize
patients with optimal placement of the drug
and perception of its complete disintegration
may be a useful component of individualized
Fig. 1 Complete disintegration time of sublingual fenta-
nyl as a function of dose. One-way analysis of variance
among 3 dose groups of sublingual fentanyl (P = 0.4313)
Fig. 2 Complete disintegration time of sublingual fenta-
nyl as a function of sex (unpaired t test, P = 0.4090)
Fig. 3 Complete disintegration time of sublingual fenta-
nyl as a function of age (linear regression, P = 0.3552)
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care in the management of breakthrough cancer
pain [25].
Effective treatment of breakthrough cancer
pain may be influenced by patient acceptance of
the drug, and it is important to note that the
present study focused on disintegration time and
not pain relief. In addition, the open-label, non-
randomized design of this study limits the
conclusions that can be drawn. Furthermore, the
study did not include crossover to a comparator
treatment such as a matching placebo sublingual
tablet or a different transmucosal fentanyl
product. Finally, the small sample size of this
study may not have provided adequate statistical
power to detect differences between groups.
Therefore, additional studies are needed to assess
the degree to which disintegration time is of
practical importance in the willingness of patients
to switch from their current treatment to
sublingual fentanyl.
CONCLUSIONS
Sublingual fentanyl tablets of all doses dissolved
rapidly, with an average time to complete
disintegration of \2 min. This compares very
favorably to other solid forms of transmucosal
immediate release fentanyl, each having dwell
times of approximately 15–30 min until
complete disintegration.
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